[37] Tamoxifen has been explored as an ovarian cancer therapy, [38, 39] and inhibition of CYP2D6 by some SSRIs (most notably fluoxetine and paroxetine) could reduce effective tamoxifen utilization in ovarian cancer patients through decreased generation of active metabolites. Here, CYP2D6 is linked to ovarian carcinoma.